The increasing problem of fungal infections in the immunocompromised host

Journal de Mycologie Medicale

Volumn 6, Issue SUPPL. 1, 1996, Pages 1-6

  Dromer, F ^a   Dupont, B ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

nosocomial infections; opportunistic infections; resistance; systemic mycoses

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPERGILLUS; CANCER CHEMOTHERAPY; CANDIDA; CONFERENCE PAPER; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; ORGAN TRANSPLANTATION; PROGNOSIS;

EID: 0029842761     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Anaissie E, Bodey GP, Kantarjian H, Ro J, Vartivarian H, Hopfer R et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989;11:369-787.
2. Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994;170:384-9.
3. Armstrong D. Problems in management of opportunistic fungal diseases. Rev Infect Dis 1989;11(Suppl. 7):S1591.
4. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994;8:787-92.
5. Banarjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T et al. Secular trends in nosocomial primary bloodstream infections in the United states, 1980-1989. Am J Med 1991;91 (suppl 3B):86S-9S.
6. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. In vitro activity of itraconazole against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:1530-3.
7. Bart-Delabesse E, van Deventer H, Goessens W, Poirot JL, Lioret N, van Belkum A et al. Contribution of molecular typing methods and antifungal susceptibility testing to the study of a candidemia cluster in a burn care unit. J Clin Microbiol 1995;33: 3878-83.
8. Becq-Sagué CM, Jarvis WR, the National Nosocomial Infections Surveillance Program. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51.
9. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of Granulocyte Macrophage Colony Stimulating Factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993;17:705-7.
10. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type I. Antimicrob Agents Chemother 1993;37:2449-53.
11. Chabasse D. Les nouveaux champignons opportunistes apparus en médecine. J Mycol Méd 1994;4:9-28.
12. Chavanet P, Lopez J, Grappin M, Bonnin A, Duong M, Waldner A et al. Crosssectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994;8:945-50.
13. Cunliffe NA, Denning DW. Uncommon invasive mycoses in AIDS. AIDS 1995;9:411-20.
14. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York city. Clin Infect Dis 1994;19: 1029-33.
15. Dellion S, Improvisi L, Dupont B, Dromer F. Diversity among yeasts isolated from patients with AIDS and oral candidosis, especially regarding fluconazole susceptibility. J Mycol Méd 1995;5: 98-101.
16. Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opinion Infect Dis 1994;7:456-62.
17. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-8.
18. Dromer F. The detection of fungal antigenemia. In: Rapid methods and automation in microbiology and immunology, edited by Hampshire, UK. Intercept Ltd: 1994, pp. 13-22.
19. Dromer F, Moulignier A, Dupont B, Guého E, Baudrimont M, Improvisi L et al. Myeloradiculitis due to Cryptococcus curvatus in AIDS. AIDS 1995;9:395-6.
20. Dromer F, Ronin O, Dupont B, les membres du Groupe d'Étude des Mycoses Opportunistes. Données épidémiologiques du Centre de Référence sur le cryptococcose en France. Méd Mal Infect 1994;245:576-9.
21. Dupont B. Invasive fungal infections caused by yeasts as emerging pathogens. Infect Dis Clin Pract 1994;(suppl. 2):243-52.
22. Dupont B, Denning DW, Mamot D, Sugar A, Viviani MA, Sirisanthana T. Mycoses in AIDS patients. J Med Vet Mycol 1994;32(Suppl. 1):65-77.
23. Fisher-Hoch SP, Hutwater L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995;21:897-904.
24. Garcia-Hermoso D, Dromer F, Improvisi L, Provost F, Dupont B. Fluconazole (FCZ) concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with FCZ. Antimicrob Agents Chemother 1995;39:656-60.
25. Gautheret A, Dromer F, Bourhis JH, Andremont A. Trichoderma pseudokoningii as a cause of fatal infection in a bone marrow transplant recipient. Clin Infect Dis 1995;20:1063-4.
26. Goff DA, Koletar SL, Buesching WJ, Bamishan J, Fass RJ. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis 1995;20:77-83.
27. Gradon JD, Timpone JG, Schnittman SM. Emergence of unusual opportunistic pathogens in AIDS: a review. Clin Infect Dis 1992;15:134-57.
28. Graybill JR, Craven PC, Mitchell LF, Drutz DJ. Interaction of chemotherapy and immune defenses in experimental murine cryptococcosis. Antimicrob Agents Chemother 1978;14:659-67.
29. Guého E, Improvisi L, de Hoog GS, Dupont B. Trichosporon in humans: a practical account. Mycoses 1994;37:3-10.
30. Heinic GS, Stevens DA, Greenspan D, McPhail LA, Dodd CL, Stringari S et al. Fluconazole-resistant Candida in AIDS patients. Oral Surg Oral Pathol 1993;76:711-5.
31. Hibberd PL, Rubin RH. Clinical aspects of fungal infections in organ transplant recipients. Clin Infect Dis 1994;79(Suppl. 1): S33-40.
32. Huffnagle KE, Gander RM. Evaluation of Gen-Probe's Histoplasma capsulatum and Cryptococcus neoformans AccuProbes. J Clin Microbiol 1993;31:419-21.
33. Just G, Steinheimer D, Schnellbach M, Böttinger C, Helm EB, Stille W. Change of causative organisms under antifungal treatment in immunocompromised patients with HIV-infections. Mycoses 1989;32(Suppl. 2):47-51.
34. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-432.
35. Marcon MJ, Powell DA. Human infections due to Malassezia spp. Clin Microbiol Rev 1992;5:101-19.
36. Merz WG. Detection of fungal-specific metabolites and nucleic acid sequences for the diagnosis of fungal infections. In: Rapid methods and automation in Microbiology and Immunology, edited by Hampshire, UK. Intercept: 1994, pp. 23-34.
37. Morrison VA, Weisdorf DJ. Alternaria: a sinonasal pathogen of immunocompromised hosts. Clin Infect Dis 1993;16:265-70.
38. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994;7:479-504.
39. Paya CV. Fungal Infections in solid-organ transplantation. Clin Infect Dis 1993;16:677-88.
40. Pfaller M. Epidemiology and central of fungal infections. Clin Infect Dis 1994;19(Suppl. 1):S8-13.
41. Rinaldi MG. Problems with the diagnosis of invasive fungal diseases. Rev Infect Dis 1991;13:493-5.
42. Rosetti F, Brawner DL, Bowden R, Meyer WG, Schoch HG, Fisher L et al. Fungal liver infections in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995;20:801-11.
43. Samaranayake YH, Samaranayake LP. Candida krusei: biology, epidemiology, pathogenicity and clinical manifestation of an emerging pathogen. J Med Microbiol 1994;41:295-310.
44. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91 (Suppl. 3B).
45. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 1993;17(Supp1. 2):S487-91.
46. Walsh TJ, Gonzales C, Roilides E, Mueller BU, Ali N, Lewis LL et al. Fungemia in children infected with the Human Immunodeficiency Virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin Infect Dis 1995;20:900-6.
47. Wheat J. Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev 1995;8:146-59.
48. Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986;314:83-8.
49. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25.
50. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;18:1274.
51. Word GM, McCormack JG, Muir DB, Ellis DH, Ridley MF, Pritchard R et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992;14:1027-33.